Pfizer delays patent cliff for blockbuster Vyndamax
Article
Pfizer delays patent cliff for blockbuster Vyndamax
Source
Pfizer is staving off Vyndamax competition for another two years. The drug, also known as tafamidis, is among Pfizer’s top three best-selling medicines and vaccines. Vyndamax is approved for a heart ...
Related
9 events DateTypeEvent
Apr 28 ScanHealthcare Scan Apr 26 ScanHealthcare Scan May 1 ArticleChannel Beats SKU — Does the GLP-1 Distribution Thesis Generalize? May 5 CatalystPFE earnings Apr 13 Scan2 — HEALTHCARE SCAN Apr 10 ScanHealthcare Scan Apr 3 ScanHealthcare Scan Apr 3 ScanBiotech Scan Mar 31 ScanHealthcare Scan Source links
Tweets, videos, filings, articles, and source pages tied to this read.
endpoints.newsendpoints.news